Reduced Immune Activation During Tenofovir–Emtricitabine Therapy in HIV-Negative Individuals

Journal of Acquired Immune Deficiency Syndromes - United States
doi 10.1097/qai.0000000000000529
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Abacavir–Lamivudine Versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy

New England Journal of Medicine
Medicine
2009English

The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B.

Journal of Acquired Immune Deficiency Syndromes
Infectious DiseasesPharmacology
2016English

Is Tenofovir/Emtricitabine Teratogenic?

Therapeutic Advances in Drug Safety
Pharmacology
2013English

First-Line Antiretroviral Therapy With Efavirenz Plus Tenofovir Disiproxil Fumarate/Emtricitabine or Rilpivirine Plus Tenofovir Disiproxil Fumarate/Emtricitabine: A Durability Comparison

HIV Medicine
Health PolicyInfectious DiseasesPharmacology
2018English

Reduction of Immune Activation With Chloroquine Therapy During Chronic HIV Infection

Journal of Virology
Insect ScienceImmunologyMicrobiologyVirology
2010English

Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected Patients

ISRN Gastroenterology
2011English

Resistance Analysis of Bictegravir/Emtricitabine/Tenofovir Alafenamide in HIV-1 Treatment-Naïve Patients Through 48 Weeks

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2019English

Pharmacokinetic and Safety Analyses of Tenofovir and Tenofovir-Emtricitabine Vaginal Tablets in Pigtailed Macaques

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2014English

Altered Metabolism of Gut Microbiota Contributes to Chronic Immune Activation in HIV-infected Individuals

Mucosal Immunology
AllergyImmunology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy